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Many studies seek to explore the impact of extrinsic soluble factors present in serum, interstitial ﬂuids or cell-
conditioned media on cells in vitro. A convenient approach to elucidate the effects of a particular factor is its se-
lective neutralization. However, intrinsic production of soluble factors such as cytokines by the cultured cells is
common and can have an impact via autocrine mechanisms. The addition of cytokine-speciﬁc neutralizing anti-
bodies leads to neutralization of the targeted factors irrespective of their source and affects paracrine and auto-
crine effects alike. Thus, neutralization assays are not suitable to irrevocably demonstrate that the examined
factors exert their effect via a paracrinemechanism.Wewere interested in investigating the impact of immuno-
suppressive factors present in ovarian carcinoma-associated ascites by dissecting paracrine versus autocrine ef-
fects of interleukin 10 (IL-10) and prostaglandin E2 (PGE2) on the activation of monocyte-derived dendritic cells
(DC). We explored several methods of depletion based on introduction of the neutralizing antibodies bound to
beads. Here we describe the pitfalls of the investigated depletion approaches and show the importance of mon-
itoring the presence of residual neutralizing antibodies in the sample upon depletion, which impacts on the suit-
ability of the approach to distinguish paracrine from autocrine effects. Only one of three investigated approaches
showed no dislocation of neutralizing antibody from the beads into the sample. This method, which is based on
covalently linking antibody to magnetic beads harbouring a reactive group allowed for the complete removal of
the investigated factors from ascites and represents an elegant tool to elucidate immunoregulatory or
-stimulatory cytokine networks in considerably more depth than the use of neutralizing antibodies in cell
cultures alone can contribute.
© 2017 The Authors. Published by Elsevier B.V. This is an open access article under the Open Government License
(OGL) (http://www.nationalarchives.gov.uk/doc/open-government-licence/version/3/).
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1. Introduction
Development of ascites is a hallmark symptom of the late stages of
ovarian carcinoma, and soluble tumour-associated factorswithin can af-
fect disease progression and interfere with anti-tumour vaccination
strategies (Giuntoli et al., 2009; Yigit et al., 2011). Studies of cytokines
in the tumour environment are frequently conducted in vitro by addi-
tion of biologicalﬂuids such asmalignant ascites or tumour-conditioned
media to cell cultures, while functional characterization of individual
proteins is attempted by their selective antibody-mediated neutraliza-
tion. In our laboratory, we investigate how factors within ovarian
carcinoma-associated ascites affect Toll-like receptor (TLR)-mediated
activation of monocyte-derived DC. Ovarian carcinoma-associated
ascites contains a complexmixture of anti- and pro-inﬂammatory factors
which can differ signiﬁcantly between individual patients andwhich has
the potential to inﬂuence the activation of various cell types (Chen et al.,
2009; Mustea et al., 2009; Nowak et al., 2010; Yigit et al., 2010). We ob-
served that ascites partially impairs DC activation in response to TLR ag-
onists in vitro (unpublished data) and we decided to selectively
neutralize various factors using speciﬁc antibodies to identify the mech-
anism by which ascites reduces DC activation. IL-10 is one well-known
immunosuppressive factor present in ovarian carcinoma ascites and has
previously been implicated to play an important role in disease progres-
sion and prognosis (Punnonen et al., 1998; Santin et al., 2001; Mustea et
al., 2006; Zhou et al., 2007; Giuntoli et al., 2009; Yigit et al., 2011;Matte et
al., 2012).We therefore considered IL-10 to be a candidate protein poten-
tially important to the immunosuppressive effects of ascites. Tumour
cells, but also tumour-associated antigen-presenting cells have been
shown to produce IL-10 and are thought to contribute to the IL-10 levels
in ascites (Melichar et al., 1998; Loercher et al., 1999; Zhou et al., 2007).
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Incidentally, DC produce IL-10 upon TLR activation (Jarrossay et al., 2001;
Boonstra et al., 2006). IL-10 induction under pro-inﬂammatory condi-
tions is an important protective mechanism of the immune system
preventing excessive and uncontrolled immune activation. Because of
the induction of DC-derived IL-10, blocking experiments based on the ad-
dition of neutralizing antibodies to DC cultures cannot conclusively attri-
bute the suppression to ascites-derived paracrine IL-10.
To gain a better understanding of the inﬂuence of ascites on DC acti-
vation, we explored the relative importance of ascites-derived versus au-
tocrine IL-10 in our experimental system. Our aim was to deplete this
protein from ascites before addition of the ﬂuid to cell cultures, allowing
us to discriminate between the distinct inﬂuences of autocrine versus
paracrine IL-10. The establishment of a suitable protocol proved challeng-
ing, butwe eventually succeeded and present here amethod for selective
depletion of proteins from ascites. In addition to IL-10, we expanded the
application to another immunosuppressive factor, namely PGE2 (Kalinski,
2012), which we had also identiﬁed as a candidate protein in malignant
ascites that may partially impair DC activation (unpublished data).
2. Material and methods
2.1. Patient specimens
The collection of ascites for this studywas approved by the Guy's Re-
search Ethics Committee (REC Number: 09/H0804/45). Informed con-
sent was obtained from all participants. Ascites from patients suffering
fromadvanced stage (FIGO stage III or IV) high grade serous ovarian car-
cinoma was collected by paracentesis (St Thomas' Hospital, London,
UK). Upon receipt, ascites samples were centrifuged for 10 min at
270g, allowing the separation of the ﬂuid into a cellular fraction and
non-cellular supernatant. Only the non-cellular supernatant was used
in this study. The material was stored in aliquots at −80 °C. Upon
thawing, before cytokine depletion and use in cell cultures, the non-
cellular ﬂuid was passed through a syringe-driven sterile ﬁlter of
0.2 μm pore size (Appleton Woods, Birmingham, UK).
2.2. Neutralizing antibodies
IL-10 neutralizing antibody (clone 25,209; RRID: AB_358066) and
the corresponding mouse IgG2b isotype control antibody (clone
20,116; RRID: AB_357344) were from R&D Systems (Abingdon, UK).
Neutralizing αPGE2 antibody (clone 2B5; mouse IgG1; RRID: AB_
327973) was from Cayman Europe (Tallinn, Estonia) and the corre-
sponding mouse IgG1 isotype control antibody (clone 11,711; RRID:
AB_357346) was purchased from R&D Systems.
2.3. Depletion of IL-10 using protein G-coated agarose beads
IL-10 neutralizing antibody or relevant mouse IgG2b isotype
control antibody were added to sterile ﬁltered ascites at concentrations
of 5 μg/ml or 20 μg/ml and the samples were incubated for 30 min at
4 °C. After addition of Protein G agarose beads (Thermo Scientiﬁc,
Cramlington, UK) (100 μl beads per 1ml of ascites) the sampleswere in-
cubated for 30 min at room temperature (RT). With a binding capacity
of 2 mg of antibody per 100 μl the amount of Protein G-coupled agarose
beads exceeded the amount of used antibody by 400× (5 μg/ml) and
100× (20 μg/ml) fold, respectively. Samples were then centrifuged at
420g for 5 min, and the supernatant was carefully harvested. Centrifu-
gation at identical speed and durationwas repeated to ensure complete
removal of residual agarose beads.
2.4. Depletion of IL-10 using protein G coated magnetic beads
For immobilization of αIL-10 antibody or relevant mouse IgG2b
isotype control antibody on PureProteome Protein G Magnetic Beads
(Millipore, Livingston, UK), the manufacturer's protocol was followed.
Brieﬂy, 50 μl Protein G Magnetic Beads were incubated with 10 μg/ml
αIL-10 neutralizing antibody or respective mouse IgG2b isotype control
antibody for 10 min at RT with continuous mixing. Beads were then
washed in 500 μl PBS containing 0.1% Tween 20 with the help of the
PureProteome magnetic stand (Millipore). Subsequently, 200 μg chro-
matographically puriﬁed mouse IgG (Invitrogen, Paisley, UK) was added
to each sample in order to saturate vacant IgG-binding sites on Protein
G Magnetic Beads. Incubation for 10 min at RT with continuous mixing
was followed by 3×washing in 500 μl PBS containing 0.1% Tween 20. An-
tibody-coated Protein G Magnetic Beads were added to 1 ml sterile ﬁl-
tered ascites and incubated for 1 h or overnight at 4 °C with continuous
mixing. After incubation, magnetic beads were removed by placing the
microcentrifuge tubes into the magnetic stand and transfer of the bead-
free ascites into a freshmicrocentrifuge tube. This procedure was repeat-
ed two more times to ensure complete removal of magnetic beads.
2.5. Depletion of IL-10 or PGE2 using NHS coated magnetic beads
For conjugation of αIL-10 antibody, αPGE2 antibody or relevant
isotype control antibodies (mouse IgG2b or IgG1) to PureProteome N-
Hydroxysuccinimide (NHS) FlexiBind Magnetic Beads (Millipore), the
manufacturer's protocol was followed. To ensure successful coupling
of antibody to the PureProteome NHS Magnetic Beads, the antibodies
must be present at a concentration of 2 mg/ml or above. The stock
concentration of both isotype control antibodies as well as the αIL-10
antibody was 500 μg/ml and a further concentration was therefore re-
quired to reach 2 mg/ml. For this, a deﬁned amount of antibody
(100 μg) in solutionwas pipetted into anAmicon®Ultra-0.5 30KDevice
(Millipore), and centrifuged at 14,000 ×g for 7 min. The obtained
concentrated antibody solution was recovered from the device and the
volumewas adjusted to 50 μl with PBS, resulting in a ﬁnal antibody con-
centration of 2mg/ml. TheαPGE2 antibodywas supplied at a concentra-
tion of 2 mg/ml and no further concentration was therefore required.
For the coupling of antibodies to PureProteome NHS Magnetic
Beads, 100 μl bead slurry was added to a microcentrifuge tube (Costar®
Sigma-Aldrich), and beads were washed 1× with ice-cold equilibration
buffer (1 mM HCl; Millipore) with the help of PureProteome Magnetic
Stand (Millipore). 50 μl of respective antibody solution (2 mg/ml) was
added immediately, followed by incubation for 2 h at RT. Subsequently,
beads were washed 5× in the magnetic stand with quench buffer
(100 mM Tris-HCl, 150 mM NaCl, pH 8.0; Millipore) followed by an in-
cubation of 2 h at RT in quench buffer. The beads were subsequently
washed 4× with wash/coupling buffer (PBS, pH 7.4; Millipore) and ﬁ-
nally resuspended in 100 μl of PBS. Antibody-coated beads were stored
at 4 °C until used. For the depletion, the αIL-10 or αPGE2 antibody-
coated beads were incubated with ascites from ovarian carcinoma
patients (20 μl antibody-conjugated bead slurry per 1 ml ascites) over-
night at 4 °Cwith continuousmixing. To control for the speciﬁcity of the
depletion, isotype control mouse IgG coated beads were incubated with
ascites samples for mock depletion. After overnight incubation, beads
were removed from ascites samples using the PureProteome Magnetic
Stand. Ascites depleted of IL-10, PGE2 and mock-depleted samples
were stored at−80 °C until their use in activation assays.
2.6. Detection of IL-10 or PGE2 in depleted ascites samples
To verify successful depletion of IL-10 or PGE2 from ascites, levels of
IL-10 were measured by Flow Cytomix® human IL-10 Simplex Kit
(eBioscience, Hatﬁeld, UK). The manufacturer's protocol for Simplex
Kits was followed using dilution buffers, reagents and a 96-well ﬁlter
plate provided in the Flow Cytomix Basic Kit (eBioscience). Samples
were transferred into FACS tubes for acquisition on the FACS Canto II
(BD), and data was analyzed and quantiﬁed using Flow Cytomix®
Analysis Software (eBioscience).
Formeasurement of PGE2, High Sensitivity PGE2 Parameter Assay kit
(Arbor Assays, Ann Arbor, MI, U.S.A.) was used. The manufacturer's
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protocol was followed, using a pre-coated 96-well plate, dilution buffers
and reagents provided in the kit. Optical density (OD) wasmeasured on
an ELISA microplate reader (Biorad, Hemel Hempstead, UK) at 450 nm
and all samples were evaluated with reference to the standard curve
for PGE2 quantiﬁcation.
2.7. Detection of mouse IgG1 and mouse IgG2b in depleted ascites samples
For detection of mouse IgG1 or mouse IgG2b in ascites after
depletion, Immuno MAXISORP ELISA 96-well plates (Nunc, Roskilde,
Denmark) were coated with puriﬁed anti-mouse IgG1 antibody
(rat IgG clone RMG1–1; BioLegend; RRID: AB_315061) or puriﬁed
anti-mouse IgG2b antibody (rat IgG clone RMG2b-1; BioLegend;
RRID: AB_315065) diluted in PBS (for both anti-mouse IgG1 and
IgG2b 2 μg/ml coating antibody concentration was used). Plates were
incubated overnight at 4 °C, and subsequently washed twice with
wash buffer (PBS containing 0.05% Tween 20) before non-speciﬁc bind-
ing sites were blocked by incubating all wells with PBS containing 10%
heat-inactivated FCS; Sigma Aldrich) for 2 h at RT. After washing
twice, standard (mouse IgG1 clone 11,711 or mouse IgG2b clone
20,116; both R&D Systems) and samples were added to triplicate
wells at appropriate dilutions in PBS. The anticipated IgG concentrations
in ascites were difﬁcult to estimate, and therefore a wide range of sam-
ple dilutions (undiluted, 1:10, 1:100, 1:1000, 1:10,000) was used in all
ELISA experiments to ensure that the values fell within the sensitivity
range of the assay. After overnight incubation at 4 °C, plates were
washed 4×withwash buffer and biotinylated anti-mouse IgG detection
antibody (goat Ig clone Poly4053; BioLegend; RRID: AB_315006) was
added to all wells (0.5 μg/ml ﬁnal antibody concentration) and allowed
to incubate for 1 h at RT. After 4× washing, ExtrAvidin®-Alkaline Phos-
phatase (Sigma-Aldrich) was added to all wells (1:5000 dilution in PBS)
and plates were incubated for 1 h at RT. Plates were washed 4×, follow-
ed by application of SIGMAFAST pNitrophenyl phosphate (PNPP) and
buffer Tablets (Sigma-Aldrich) dissolved in deionised water. The OD
was measured on an ELISA microplate reader (Biorad) at 405 nm and
all sampleswere evaluatedwith reference to the standard curve for pro-
tein quantiﬁcation. The ELISA had a sensitivity of 0.1 ng/ml for both
mouse IgG2b and mouse IgG1.
2.8. Detection of human IgG in ascites samples
For detection of human IgG in ascites samples before and after de-
pletion, Human IgG total Ready-SET-Go!® kit (Affymetrix eBioscience,
Hatﬁeld, UK) was used. The manufacturer's protocol was followed,
using Immuno MAXISORP ELISA 96-well plates together with antibod-
ies, dilution buffers and reagents provided in the kit. The OD was mea-
sured on an ELISA microplate reader at 450 nm and all samples were
evaluated with reference to the standard curve for IgG quantiﬁcation.
2.9. Activation assay of monocyte-derived DC with LPS and ascites
The collection of peripheral blood for this studywas approved by the
Guy's Research Ethics Committee (REC Number: 09/H0804/45). In-
formed consent was obtained from all participants who gave blood by
venipuncture. Peripheral blood from healthy volunteers was obtained
by venipuncture and collected in heparinized vacutainer tubes (BD). Pe-
ripheral blood mononuclear cells (PBMC) were obtained from whole
blood by Ficoll (Lymphocyte Separation Medium 1077; PAA Laborato-
ries, Yeovil Somerset, UK) density gradient centrifugation. CD14+
monocytes were isolated from PBMC by negative selection using the
EasySep® Human Monocyte Enrichment Kit (StemCell Technologies,
Grenoble, France) following the manufacturer's instructions. Enriched
CD14+ monocytes were seeded on 6-well-plates at a density of 6-
9 × 106 cells/well in 3 ml complete RPMI 1640 medium supplemented
with 10% FCS, 2mMglutamine, 100 U/ml penicillin, 100mg/ml strepto-
mycin and 50 μM 2-Mercaptoethanol. Granulocyte-macrophage colony
stimulating factor (GM-CSF) and IL-4 (both R&D Systems) were added
at a concentration of 20 ng/ml each. Cells were cultured at 37 °C in a
5% CO2 atmosphere for 7 days. GM-CSF and IL-4 were replenished on
day 2 and day 5 along with 500 μl fresh complete RPMI 1640 medium
per well. Cells were harvested on day 7 of culture. Subsequently, mono-
cyte-derived DC were seeded on 96-well tissue culture plates at a den-
sity of 1 × 105 cells/well in complete RPMI 1640 medium, with a ﬁnal
well volume of 200 μl. Triplicate wells were used for all samples. The re-
agents were added to the cells in the following order: First the neutral-
izing or control antibody was added, followed by the ascites and then
the LPS. TLR4 agonist LPS was used at 1 μg/ml, and IL-10 depleted or
undepleted, sterile ﬁltered ascites was added to respective wells to
reach 10% ﬁnal cell culture concentration. αIL-10 neutralizing antibody
ormouse IgG2b isotype control antibodywere added at a concentration
of 5 μg/ml where indicated. Cells were incubated for 18 h overnight at
37 °C in a 5% CO2 atmosphere. Supernatants were harvested and ana-
lyzed for IL-6 levels by ELISA.
2.10. Detection of IL-6 levels in cell culture supernatants
Immuno MAXISORP ELISA 96-well plates were coated with 4 μg/ml
αIL-6 capture antibody (rat IgG1 clone MQ2-13A5; BD; RRID: AB_
398568) diluted in 0.1 M Na2HPO4, pH 9.0 and incubated overnight at
4 °C. Plates were washed 2× with PBS containing 0.05% Tween 20 and
non-speciﬁc binding sites were blocked by incubating all wells with
blocking buffer (PBS containing 2.5% FCS and 0.02% NaN3) for 2 h at
RT. After washing twice, IL-6 standard (BD) and samples were added
to triplicate wells at appropriate dilutions in blocking buffer. Samples
without LPSweremeasured neat. Samples stimulatedwith LPSwere di-
luted 1:50 in order to ensure that the values fell within the sensitivity
range of the assay. After overnight incubation at 4 °C, plates were
washed 4× and αIL-6 detection antibody (rat IgG2a clone MQ2-39C3;
BD; RRID: AB_395470) diluted in blocking buffer was added to all
wells at a concentration of 2.5 μg/ml and allowed to incubate for 1 h
at RT. After four washes, ExtrAvidin®-Alkaline Phosphatase was added
to all wells and plates were incubated for 1 h at RT. Again plates were
washed 4× followed by application of SIGMAFAST PNPP and buffer
Tablets dissolved in deionised water. OD was measured on an ELISA
microplate reader and all samples were evaluated with reference to
the standard curve for IL-6 quantiﬁcation.
2.11. Statistical analysis
Datawere analyzed using PRISMGraph Software (La Jolla, California,
U.S.A.). Appropriate statistical tests were applied for different experi-
ments, taking into consideration the composition of each experiment,
relevant experimental cohorts and scientiﬁc questions. Differences
were considered signiﬁcant at a p-value b 0.05.
3. Results
3.1. Depletion of IL-10 from ovarian carcinoma associated ascites usingαIL-
10 antibody and protein G-coupled agarose beads
The initial approachwe took to deplete IL-10 from ascites comprised
addition of IL-10 speciﬁc neutralizing antibody to ascites, enabling IL-10
in ascites to bind to this antibody, forming antibody-antigen complexes.
Subsequently, we intended to remove such complexes by centrifugation
after addition of agarose beads coated with Protein G, a streptococcal
cell wall protein with a high afﬁnity to the Fc and Fab regions of immu-
noglobulins (Grubb et al., 1982; Kraulis et al., 1996). The afﬁnity of Pro-
tein G varies considerably for antibodies of different isotypes and host
species. Its very high afﬁnity for mouse IgG2b antibody, the isotype of
the αIL-10 neutralizing antibody, made Protein G a suitable candidate
for this depletion.
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In our initial experiment, we used two different concentrations of
αIL-10 neutralizing antibody. Two ovarian carcinoma ascites samples
were incubated with 5 μg/ml αIL-10 antibody, while for four ascites
samples, the concentration of 20 μg/ml αIL-10 antibody was chosen.
Todeterminewhether IL-10was successfully removed fromall samples,
the depletion was veriﬁed by measurement of IL-10 in the depleted
samples. Indeed, IL-10 was not detectable in the samples depleted
with the antibody concentration of 20 μg/ml (data not shown). While
this could be interpreted as successful IL-10 depletion from ascites, we
could not exclude the possibility that complexes of IL-10 andαIL-10 an-
tibody were still present and that IL-10 had, in fact, not been depleted
butwas simply neutralized and therefore not detectable. Evenmore im-
portantly, we had to exclude the possibility that unbound αIL-10 anti-
body with the capacity to neutralize autocrine DC-derived IL-10 had
remained in the ascites samples undergoing the depletion procedure.
We therefore determinedwhetherαIL-10 antibody had been complete-
ly removed by Protein G agarose beads bymeasuring the concentration
of mouse IgG2b antibody in the depleted ascites samples (Fig. 1A). The
two samples depleted with a concentration of 5 μg/ml αIL-10 antibody
showed levels of approximately 4 μg/ml mouse IgG2b, indicating that
80% of the αIL-10 antibody remained in the supernatant after centrifu-
gation. Among the four samples depleted using 20 μg/ml, the IgG2b con-
centrations ranged from 13 to 17 μg/ml. The residual αIL-10 antibody
posed a considerable problem, as upon addition of the depleted ascites
to cell cultures, residual unbound IL-10-speciﬁc antibody could poten-
tially neutralize autocrine IL-10.
Given that ascites is abundant with soluble proteins including im-
munoglobulins (Yildirim et al., 2002), we hypothesized that the Protein
G-coated agarose beads not only reacted with the IL-10-speciﬁc mouse
antibody, but also bound to human immunoglobulins present in ascites.
Competition between the human immunoglobulins and theαIL10 anti-
body for binding by protein G-coupled agarose beads could explainwhy
the depletion of the latter was inefﬁcient. To explore whether this was
the case, wemeasured the concentration of human IgG in ascites before
depletion and thereafter (Fig. 1B). In all six ascites samples, we detected
reduced human IgG levels after depletion, indicating that human IgG
was being partially depleted with the Protein G-coated agarose beads
used in this experiment. The levels of IgG in different ascites samples
differed considerably, and it appears that in samples with higher IgG
content, the reduction in IgG levels after depletion was particularly dra-
matic. These ﬁndings support the notion that direct competition with
human IgG in ascites can interfere with the depletion of particular asci-
tes-associated factors using neutralizing antibodies in combinationwith
protein G-coupled beads, as schematically illustrated in Fig. 1C.
To summarize, the speciﬁc depletion of IL-10 from ovarian carcino-
ma ascites using Protein G-coated agarose beads for removal of com-
plexes of IL-10 and αIL-10 antibody was not successful, and a different
protocol for IL-10 depletion had to be identiﬁed.
3.2. Depletion of IL-10 from ascites using magnetic protein G beads pre-
coated with αIL-10 speciﬁc neutralizing antibody
Despite the problems we encountered with the use of Protein G
coated agarose beads as explained above, Protein G remained an agent
worth considering for our purposes because of its very high afﬁnity to
immunoglobulins and its frequent use in antibody puriﬁcation and im-
mobilization protocols. To avoid the direct competition for binding sites
between neutralizing antibody and ascites-intrinsic proteins, in our
next approachwe pre-coatedmagnetic Protein G beadswithαIL-10 an-
tibody before addition of such complexes to ascites samples. We hoped
that competition between the neutralizing IL-10-speciﬁc antibody and
the human immunoglobulins in ascites would be reduced if the former
had been bound tomagnetic Protein G-coated beads prior to addition to
ascites samples.
The binding capacity of the usedmagnetic beads coatedwith Protein
Gwas very high (175 μg IgG per 50 μl according to the supplier), and sat-
urating the beads using αIL-10 neutralizing antibody was not feasible
due to the high costs. However, we were reluctant to use partially satu-
rated Protein G beads, since our previous protocol has shown that Pro-
tein G binds human IgG from ascites, leading to its partial depletion
and resulting in an altered composition of ascites samples. To avoid
this, after coating beads with αIL-10 speciﬁc antibody, we saturated
the beads using chromatographically puriﬁed mouse IgG before using
the pre-coated beads for depletion of IL-10 from ascites.
In our ﬁrst depletion attempt with this method, we incubated three
ascites samples with the pre-coated beads overnight with continuous
mixing. After removal of bead complexes by magnetic separation, we
measured IgG2b levels in the depleted samples. The amount of αIL-10
antibody used to pre-coat the magnetic beads had been 10 μg. Disap-
pointingly, the detected levels ofmouse IgG2b in these samples reached
levels of 10 μg or beyond (Fig. 2A), indicating that during incubation,
αIL-10 antibody and/or chromatographically puriﬁed mouse IgG
antibody had dissociated from the beads. We suspected that this may
have been due to the long overnight incubation time, and hence
Fig. 1. Depletion of IL-10 from ascites using αIL-10 neutralizing antibody and Protein G-
coated agarose beads. (A) Levels of mouse IgG2b αIL-10 neutralizing antibody in ascites
samples were measured after depletion of IL-10 using Protein G-coated agarose beads.
IL-10 depletion was performed with 5 μg/ml neutralizing antibody (lower panel) in two
(n = 2) and with 20 μg/ml neutralizing antibody (top panel) in four (n = 4) ascites
samples. The mouse IgG2b antibody concentration was determined by sandwich ELISA.
(B) Human IgG levels in ascites were measured by sandwich ELISA before (control) and
after depletion with Protein G-coated agarose beads (depleted). The two experiments
where 5 μg/ml neutralizing antibody was used are shown as dashed lines (n= 2), while
in the remaining experiments (n= 4) shown as solid lines, a concentration of 20 μg/ml
neutralizing antibody was used. Wilcoxon matched pairs test, two-tailed. * = p b 0.05
(C) Schematic depiction of the pitfalls encountered with this experimental approach. (1)
Neutralizing αIL-10 mouse IgG2b antibody is added to ovarian carcinoma associated
ascites, which contains a high concentration of human IgG. Upon incubation, the
neutralizing αIL-10 antibody binds IL-10 present in ascites. (2) Protein G-coated agarose
beads are added to the sample. Human IgG competes with IL-10-speciﬁc mouse IgG2b
antibody for Protein G-binding sites. (3) Centrifugation creates a pellet of agarose beads
with predominantly bound human immunoglobulins, leaving IL-10-speciﬁc antibody in
form of immune complexes with IL-10 or in form of free antibody not bound to its
antigen behind in the ascites.
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repeated the experiment with one ascites sample, reducing the incuba-
tion time to 1 h. However, even upon reduction of the incubation time,
the level of mouse IgG2b detected in the depleted ascites sample was
approaching 10 μg (Fig. 2A). To establish whether mouse IgG2b had
been displaced as a result of competition with human IgG, we deter-
mined the concentration of human IgG in ascites samples before and
after depletion (Fig. 2B). While in three samples we noted a slight de-
crease in IgG levels, this was not as prominent as seen previously with
Protein G-coated agarose beads. Since the exact interactions between
the different sources of antibodies and the magnetic Protein G-coupled
beads during incubation and magnetic separation are unknown, it re-
mains unclear to what extent αIL-10 antibody bound to Protein G-
coupled beads is replaced byhuman IgG (Fig. 2C). Independent of the al-
teration of the ascites composition with regards to human IgG levels
with this experimental protocol, the residual mouse IgG2b antibody in
depleted samples still posed a considerable problem.We therefore con-
cluded that despite its high afﬁnity to mouse IgG, Protein G is not
suitable for antibody-mediated depletion of speciﬁc cytokines from as-
cites. Collectively, these ﬁndings prompted us to explore alternative
methods for IL-10 depletion,with speciﬁc focus on improving the stabil-
ity of the binding of αIL-10 antibody to magnetic particles.
3.3. Successful depletion of IL-10 from ascites using neutralizing antibodies
covalently bound to NHS ester coated magnetic beads
Commercially available magnetic beads coated with NHS ester
groups (Millipore) have the ability to covalently bind free amine resi-
dues and can be used to permanently immobilize a range of proteins in-
cluding antibodies. Since the bonds between the neutralizing antibody
and the beads are covalent, competition with ascites-associated anti-
bodies should not pose a problem and displacement of the neutralizing
antibody should be negligible (Fig. 3A). We, therefore, hypothesized
that incubation of such antibody-coupled magnetic beads generated
with αIL-10 neutralizing antibody supports the removal of IL-10 from
ascites by magnetic separation without affecting the human IgG levels
in the samples.
We applied this method to deplete IL-10 from four ovarian carcino-
ma associated ascites samples. In order to conﬁrm that the αIL-10 neu-
tralizing antibody is not displaced from the beads during the depletion
process, we measured mouse IgG2b antibody levels in IL-10- and
mock-depleted ascites. The mouse IgG2b speciﬁc ELISA of the depleted
samples showed residual αIL-10 antibody levels of 0.5–1.3 ng/ml
(Table 1). The manufacturer's antibody titration guidelines suggest
that concentrations of this antibody of 10 ng/ml or above are necessary
to achieve neutralization of 0.1 ng/ml IL-10. In our experimental system,
the levels of autocrine IL-10 produced by monocyte-derived DC after
TLR-mediated activation reached levels of 1 ng/ml or higher (data not
shown), which would require the addition of at least 100 ng/ml of
αIL-10 antibody for successful neutralization. Further, when using asci-
tes in cell culture, it was typically not used neat but was added to cell
culture media at a ﬁnal concentration of 10%, leading to a further 10-
fold dilution of residual αIL-10 antibody. We were therefore conﬁdent
that this amount of neutralizing antibody would not interfere with au-
tocrine IL-10 production in our cell cultures and was therefore negligi-
ble. Furthermore, we determined the concentration of human IgG in
ascites before and after depletion (Fig. 3B). Our results show that
human IgG was not depleted from ascites by this protocol.
The successful depletion of IL-10was further veriﬁed by IL-10 specif-
ic bead ELISA (Fig. 3C and Table 2). IL-10 levels of 2.9–6.41 pg/ml were
detected in the depleted samples, which was considerably below assay
sensitivity of 27 pg/ml. Importantly, mock-depleted control samples
treated with beads coupled to mouse IgG2b isotype control antibody
contained IL-10 at levels identical to undepleted ascites (Fig. 3C and
Table 2).
In summary, removal of IL-10 from ascites with the use of NHS-
coated magnetic beads proved successful.
3.4. Depletion of IL-10 from ascites allows for clear distinction between in
vitro effects of paracrine ascites-derived versus autocrine IL-10
To identify the contribution of paracrine versus autocrine IL-10 in
our experimental system, we conducted an assay using monocyte-de-
rived dendritic cells (DC) activated by TLR4 agonist LPS in presence or
absence of ovarian carcinoma-associated ascites depleted of IL-10.
TLR4-mediated activation of monocyte-derived DC in presence of asci-
tes is partially impaired (Fig. 3D). Neutralization of IL-10 by addition
of a IL-10 speciﬁc antibody indeed showed dramatic impact on mono-
cyte-derivedDC activation levels, restoring LPS-induced IL-6 production
beyond the levels observed upon LPS-mediated activation in the ab-
sence of ascites (Fig. 3D). However, since IL-10 neutralization in the
presence of ascites affects autocrine DC-derived and paracrine ascites-
associated IL-10 alike, these data cannot be used to clarify their respec-
tive inﬂuence on overall activation levels. Interestingly, levels of IL-6
Fig. 2. Depletion of IL-10 from ascites using Protein G magnetic beads coated with αIL-10
neutralizing antibody. (A) Levels of mouse IgG2b αIL-10 neutralizing antibody in ascites
samples were measured after depletion of IL-10 using Protein G coated magnetic beads.
The depletion was performed with 1 h (n = 1) and 16 h (n= 3) incubation periods for
αIL-10 antibody-coated beads in ascites. The mouse IgG2b concentration was quantiﬁed
by sandwich ELISA. (B) Human IgG levels in ascites were measured by sandwich ELISA
before (control) and after depletion with Protein G-coated magnetic beads (depleted).
Values before and after 16 h incubation of ascites with antibody-coated Protein G beads
are connected by a solid line, while the dashed line indicates human IgG values in
ascites before and after an incubation of 1 h. Wilcoxon matched pairs test, two-tailed;
ns = not signiﬁcant. (C) Schematic illustration of the drawbacks of this experimental
method. (1) Protein G-coated magnetic beads are incubated with mouse IgG2b αIL-10
neutralizing antibody. The antibody binds to Protein G beads with high afﬁnity. (2) The
beads pre-coated with αIL-10-speciﬁc antibody are added to ascites to allow binding of
IL-10. Partial displacement of mouse IgG2b αIL-10 neutralizing antibody and/or mouse
IgG2b control antibody is observed. (3) After removal of Protein G magnetic beads and
bound immunoglobulins with the help of a magnet, αIL-10 antibody either with or
without bound IL-10 as well as the isotype control antibody are left behind in the ascites.
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Fig. 3. Successful depletion of IL-10 from ovarian carcinoma associated ascites using NHS magnetic beads for investigation of paracrine effects. Schematic display of IL-10 depletion with
αIL-10 antibody covalently bound tomagnetic beads. (1)Magnetic NHS ester beads are biochemically linked tomouse IgG2bαIL-10 neutralizing antibody or isotype control antibody. The
bonds between theNHS ester group on the beads and free amines of the antibody are covalent, permanently immobilizing the antibody on the bead surface. (2) Antibody-coated beads are
added to ascites and incubated overnight to allow speciﬁc binding of IL-10 to its neutralizing antibody. (3) A magnet is used to remove complexes of magnetic beads,αIL-10 neutralizing
antibody and IL-10. (B)Human IgG levels in ascitesweremeasuredby sandwich ELISAbefore (control) and after depletionαIL-10 antibody bound tomagneticNHSbeads (IL-10 depleted).
n = 4; Wilcoxon matched pairs test, two-tailed; ns = not signiﬁcant. (C) IL-10 levels in depleted versus non-depleted control or mock-depleted ascites sample were measured by
FlowCytomix bead ELISA (n= 1). The IL-10 level in the depleted sample (6.41 pg/ml) falls below assay sensitivity (27 pg/ml). (D) Monocyte-derived DC were stimulated with 1 μg/ml
LPS in the presence or absence of 10% ascites from ovarian carcinoma patients which had previously been depleted of IL-10 (IL10-ΔAF) or which had undergone mock depletion
(mock-ΔAF). Alternatively, DC cultures were treated with LPS and untreated ascites ﬂuid (AF) in the presence of αIL-10 neutralizing antibody (5 μg/ml); n = 3 (3 independent
experiments; monocyte-derived DC from 1 healthy donor, cultured with three ascites samples from three individual ovarian carcinoma patients). IL-6 levels were measured in cell
culture supernatants by sandwich ELISA. One-way ANOVA (Friedman test with Bonferroni post-test); ***p b 0.001. (E) As in D; n = 6 (monocyte-derived DC from 3 healthy donors,
cultured with two ascites samples from two individual ovarian carcinoma patients). Wilcoxon matched pairs test, two-tailed; **p b 0.01.
Table 1
Covalent binding of αIL-10 neutralizing antibody to NHS coated magnetic beads leads to
minimal residual αIL-10 antibody in depleted ascites samples.
Samples αIL-10 antibody IgG2b isotype
#1 1.3 ng/ml 2.0 ng/ml
#2 0.8 ng/ml 2.3 ng/ml
#3 0.5 ng/ml 2.5 ng/ml
#4 0.6 ng/ml 2.5 ng/ml
Levels ofmouse IgG2b antibodyweremeasured in four individual ascites samples after in-
cubation with NHS magnetic beads bound to αIL-10 or isotype control antibody. The
mouse IgG2b concentration was quantiﬁed by sandwich ELISA.
Table 2
IL-10 depletion using αIL-10 antibody bound to NHS magnetic beads leads to removal of
IL-10 from ascites.
Samples IL-10 before
depletion
IL-10 after
depletion
IL-10 after mock
depletion
#1 114.0 pg/ml 6.4 pg/ml 115.2 pg/ml
#2 48.0 pg/ml 4.4 pg/ml 49.6 pg/ml
#3 37.9 pg/ml 2.9 pg/ml 36.8 pg/ml
#4 47.8 pg/ml 5.2 pg/ml 48.2 pg/ml
Levels of IL-10 were determined in four ascites samples before and after IL-10 depletion.
IL-10 dropped considerably below assay sensitivity (27 pg/ml) in all samples depleted
with αIL-10 antibody, while levels remained unchanged in mock depleted samples. The
IL-10 concentration was quantiﬁed by Flow Cytomix bead ELISA.
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production in the presence of IL-10 neutralizing antibody are higher for
samples activated in the absence of ascites than in the presence of asci-
tes (Fig. 3E) indicating the presence of other ascites-associated factors
that reduce IL-6 induction. In order to investigate the speciﬁc role of
paracrine ascites-associated IL-10, ascites samples that had been deplet-
ed of IL-10were employed. Depletion of IL-10 prior to addition of ascites
to cell cultures leaves autocrine IL-10 unaffected while eliminating the
effect of ascites-derived IL-10. Interestingly and somewhat unexpected-
ly, addition of IL-10 depleted ascites did not restore nor even alter IL-6
production in response to LPS suggesting that paracrine ascites-derived
IL-10 does not directly contribute to the suppression of DC activation by
ovarian carcinoma-associated ascites (Fig. 3D). This ﬁnding further sup-
ports the interpretation that other immunosuppressive factors in ovar-
ian carcinoma-associated ascites impair DC activation.
3.5. Depletion of PGE2 from ascites using neutralizing antibodies covalently
bound to NHS ester coated magnetic beads
Wewanted to testwhether other immunosuppressive factors can be
successfully depleted using antibody covalently bound to NHS ester
coated beads anddecided to use this protocol for depletion of ascites-as-
sociated PGE2. For this, we coated NHS beads with PGE2-speciﬁc anti-
body or mouse IgG1 isotype control antibody and followed the
procedure as described for IL-10 for depletion of two ovarian carcinoma
ascites samples. As with the IL-10 depletion, levels of PGE2 speciﬁc neu-
tralizing antibody in the depleted samples were in the range of 1–
1.3 ng/ml and therefore negligible (Table 3), conﬁrming that detach-
ment of the covalently bound antibody during incubation with ascites
is minimal. In addition, PGE2 removal from depleted samples was veri-
ﬁedby PGE2-speciﬁc ELISA (Fig. 4). After one roundof depletion,we saw
a considerable decrease in PGE2 levels in both depleted samples. How-
ever, PGE2 levels had decreased from 158.7 pg/ml to 23.5 pg/ml in one
sample and from 597.5 pg/ml to 240.5 pg/ml in the other sample
representing an 85% and 60% reduction in PGE2 levels, respectively. It
appears that the αPGE2 antibody was used at suboptimal levels
reaching saturation and was, therefore, unable to mediate complete
PGE2 depletion. We repeated the depletion procedure, adding fresh
αPGE2-coated NHS beads to both samples for one (sample #1) or two
(sample #2) more depletion rounds. After these additional incubation
steps, PGE2 was undetectable in both samples (Fig. 4). As expected,
PGE2 levels in the ascites samples remained unaffected by mock deple-
tion with mouse IgG1 isotype control antibody-coupled beads.
In summary, we have shown that NHS-coated magnetic beads can
be covalently coupled to antibodies, and that such antibody-coupled
beads can be used for speciﬁc and complete removal of selected proteins
such as IL-10 and PGE2 from ovarian carcinoma-associated ascites.
4. Discussion
Ovarian carcinoma associated ascites is abundant with proteins, and
their characterization is of notable interest in the ﬁeld of cancer immu-
nology and immunotherapy (Kipps et al., 2013). N200 proteins can be
identiﬁed in the cell-free fraction of ascites (Gortzak-Uzan et al.,
2008), and themyriad of soluble componentsmakes selective depletion
of a particular protein challenging. To identify a suitable protocol for
successful removal of immunosuppressive factors such as IL-10 and
PGE2 from the ﬂuid, it was imperative to take the composition of ascites
into careful consideration.
In our initial depletion attempts for removal of αIL-10 antibody, we
relied on Protein G. While its high afﬁnity for murine IgG rendered Pro-
tein G an excellent candidate for binding and depletion of the neutraliz-
ing αIL-10 mouse IgG2b antibodies, its high afﬁnity to human IgG and
the abundance of the latter in ascites posed considerable obstacles
(Bjorck and Kronvall, 1984). Direct competition of human IgG with
αIL-10 antibody for Protein G binding sites not only resulted in residual
αIL-10 antibody in depleted samples, but also altered ascites composi-
tion through partial removal of human IgG by Protein G coupled
beads. Although we have not tested whether ascites-derived human
IgG inﬂuences DC in our assays,wewanted to avoid altering any param-
eters other than IL-10 or PGE2 levels in ascites, and ensure the depletion
was restricted to these proteins. Surprisingly, the level of depletion of
human IgG from the ascites samples was reduced to non-signiﬁcant
levels upon pre-incubation of the neutralizing αIL-10 antibody with
the protein G coupled magnetic beads as compared to adding beads
and neutralizing antibody to the samples without pre-incubation,
while the dislocation of neutralizing αIL-10 and/or isotype control
mouse IgG2b antibody was still immense. It is, therefore, unclear
whether the dislocation of antibody from the beads took place due to
competition with the human IgG present in the ascites or whether anti-
bodywas simplymechanically sheared off during the incubation. Unex-
pectedly, the reduction in the pre-incubation time from 16 h to 1 h did
not noticeably alter the amount of dislocated mouse IgG2b antibody, so
we decided to abandon this approach.
Since the binding of antibody to beads based on the interaction of
protein G with the antibody Fc region was not robust enough for our
purposes, we decided to pursue a strategy based on covalent linkage
of the antibody to the beads. Upon covalent binding of free amine
groups on the antibody to magnetic beads harbouring reactive NHS
ester groups, we ﬁnally achieved highly speciﬁc removal of IL-10 and
PGE2. The procedure ensures complete depletion of the desired factors
while leaving human IgG levels in depleted ascites unaffected. The
established protocol is likely to be applicable for the selective removal
of a multitude of other proteins from ascites, for which speciﬁc antibod-
ies are available. We are conﬁdent that this method is further transfer-
rable to depletion of tumour conditioned media, serum, or any other
biological ﬂuid. In this context, it is important to note that one round
of depletionwas sufﬁcient to remove IL-10but not PGE2 from the ascites
samples in our study. How many rounds are required for complete re-
moval of a targeted factor will depend on the absolute levels of the
Table 3
Covalent binding ofαPGE2 neutralizing antibody to NHSmagnetic beads leads to minimal
residual αPGE2 antibody in depleted ascites samples.
Samples αPGE2 antibody IgG1 isotype
#1 1.3 ng/ml 0.4 ng/ml
#2 1.3 ng/ml 0.2 ng/ml
Levels ofmouse IgG1αPGE2 neutralizing antibody and respective isotype control antibody
were measured in ascites samples after depletion of PGE2 using NHS magnetic beads. The
mouse IgG1 concentration was quantiﬁed by sandwich ELISA.
Fig. 4. Depletion of PGE2 from ovarian carcinoma associated ascites using NHS magnetic
beads. PGE2 levels in mock-depleted control versus PGE2-depleted ascites samples after
depletion using NHS magnetic beads coated with αPGE2 antibody. Each graph
represents one individual ascites sample (n = 2). Two (sample #1) or three (sample
#2) rounds of depletion were performed to ensure complete removal of PGE2 from
ascites. PGE2 levels were measured by sandwich ELISA.
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factor in the sample, the afﬁnity of the antibody to its ligand and the ef-
ﬁcacy of coupling the antibody to theNHSmagnetic beads andwill have
to be determined for each antibody and sample type individually. In
order to ensure complete depletion of the targeted factor in all samples,
it is imperative to determine the levels of the targeted factor before and
after depletion for all samples.
Our data clearly illustrate the vital importance of discrimination be-
tween the contributions of autocrine versus extrinsic factors. The down-
modulation of DC activation by autocrine TLR-induced IL-10 has been
described and has prompted us to clarify whether paracrine ascites-as-
sociated IL-10 contributed to the suppression in DC activation observed
in our experimental system (Moore et al., 2001; Chang et al., 2007). In
our activation assay, use of neutralizing antibodies alone deceptively
implicates IL-10 as the driving factor of ascites-induced suppression,
and it is only through the method of depletion that these observations
could be further elucidated, showing that, in fact, after complete remov-
al of IL-10 from ascites, suppression of LPS-mediated DC activation per-
sists. This implies that paracrine ascites-associated IL-10 is redundant in
our experimental systemand that factors other than IL-10within ascites
play an important suppressive role. We have followed up on this obser-
vation and have investigated the mechanism of immunosuppression
that impairs DC activation in the presence of ovarian carcinoma in a
more extensive research study (manuscript in preparation).
We demonstrate here the relevance of distinguishing the differential
inﬂuences of tumour-derived versus autocrine factors on DC and their
activation with TLR agonists. These observations can be extrapolated
and should be considered in future studies using a wide variety of cell
subsets and culture conditions. Selective depletion of proteins can con-
tribute to the elucidation of immunoregulatory or -stimulatory cytokine
networks, which constitutes an important step towards a thorough and
profound understanding of the complex interactionswithin the tumour
environment and the establishment of more elaborate immunothera-
peutic concepts.
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